Osimertinib is associated with reversible and dose-independent cancer therapy-related cardiac dysfunction
Kei Kunimasa(Kobe University), Toru Kumagai(University of Pennsylvania), Risa Kamada(Osaka International Cancer Institute), Hanako Kuhara(Osaka International Cancer Institute), Noriyuki Yamada(Miwa Hospital), Kazumi Nishino(Osaka Medical Center for Cancer and Cardiovascular Diseases), Motohiro Tamiya(Osaka International Cancer Institute), Satoshi Oizumi(Hokkaido University), Fumio Imamura(Osaka International Cancer Institute), Masashi Fujita(Kindai University), Toru Oka(Osaka International Cancer Institute), Hayato Kawachi(Osaka International Cancer Institute), Tomoya Funamoto(Itami City Hospital), Takashi Matsunaga(Shiga University of Medical Science), Yoshihiro Miyashita(Yamanashi Prefectural Central Hospital), Satoshi Hara(Itami City Hospital), Takako Inoue, Takahisa Kawamura(Osaka International Cancer Institute)
Cited by 43
Related Papers
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
|New England Journal of Medicine|2010|5.6k
Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial
|The Lancet Oncology|2019|617
Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin–paclitaxel for chemo-naïve non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002)
|Annals of Oncology|2012|555
Phase III Study, V-15-32, of Gefitinib Versus Docetaxel in Previously Treated Japanese Patients With Non–Small-Cell Lung Cancer
|Journal of Clinical Oncology|2008|365